What was the financing situation in the pharmaceutical and health sector in November? A number of pharmaceutical companies raised more than 100 million yuan in a single financing

【Pharmaceutical Network Industry News】Data statistics show that in October 2022, a total of 64 private equity investment and financing events occurred in the domestic medical and health field, a decrease of 22% month-on-month, and the total disclosed financing was about 4.
625 billion yuan, a decrease of about 9%
month-on-month.
Entering November, how is the financing situation in the pharmaceutical and health sector? Judging from public information, there have been a number of financing incidents, among which many pharmaceutical companies have raised more than
100 million yuan in a single financing.
On November 8, Thermoros Biotech announced that the company has obtained nearly 200 million yuan in C1 round financing and tens of millions of yuan in bank loans, which are jointly invested
by Guanzi Venture Capital, Tianrui Fengnian and Yixing Huarui.
It is reported that this round of financing is planned to accelerate the clinical trial and international cooperation of multiple projects in the company's R&D pipeline, as well as the preclinical development of
follow-up projects.
According to the data, Thermoro Biotech is a global innovative biotechnology company driven by innovation as the value, with the mission of alleviating and relieving the pain of patients and improving the quality of life, and is committed to the research and development
of new drugs for pain, inflammation, central nervous system and other related diseases.
Mainstream Source Biology Recently, Mainstream Source Bio announced that the company completed a series A financing
of nearly 100 million yuan.
This round of financing was led by Fuhui Venture Capital, and followed by many institutions such as Snow Exploration Capital and Dingfu Investment
.
The funds raised will be used to build the company's core technology platform and promote clinical research
in key R&D pipelines.
According to the data, Mainstream Source Biotech is a research and development biotechnology enterprise
focusing on peptide innovative drug 2.
0.
The company has developed a series of peptide drugs
with a class of new drug potential by utilizing its unique peptide conjugate drug (PDC) and multifunctional peptide drug screening and optimization platform.
At present, the company has branches in Zhongshan, Shanghai and the United States to jointly promote the global peptide new drug research and development process
.
On November 9, Skinze Biotech announced the completion of the A1 round of financing of more than 200 million yuan, this round of financing is co-led by Qiming Venture Capital, Eli Lilly Asia Fund, Jinyuan Zhanhong and China New Capital, Yuanhe Holdings, Peking University Scientific and Technological Achievements Transformation Fund (Founder Hesheng), Junshan Capital jointly invested, Fengrui Capital, Sequoia China, Jiacheng Capital and other additional investments
.
This round of financing will be used to accelerate the preclinical drug research of Shize Biologics' iPS-derived cell drug pipeline for the treatment of neurological diseases, expand the professional team and pilot production of Shize Biologics' clinical-grade iPS-derived cell drug products
.
According to the data, Shize Biotech is a Chinese biopharmaceutical company
focusing on providing large-scale and low-cost iPS-derived cell drug treatment regimens for a series of major or critical diseases represented by Parkinson's disease that have no substantive clinical solutions.
Keyi Pharmaceutical Recently, Keyi Pharmaceutical also announced the completion of the first round of financing of nearly 500 million yuan, invested by Kequan Fund established by Zhejiang Anji Development Zone
.
The funds will be mainly used for clinical trials of core products, IND declaration of core pipelines and GMP plant construction
.
According to the data, the company is a biomedical technology enterprise focusing on the research and development of innovative drugs for tumor immunotherapy and clinical application, based on clinical needs and enterprise positioning focusing on tumor immunotherapy, the company has laid out bifunctional antibodies, ADCs, solid tumor CAR-T, hematological tumor CAR-T and other R&D platforms, and developed nearly 8 FIC/BIC products
.
Recently, Yimiao Shenzhou completed a D+ round of strategic financing of hundreds of millions of yuan, which was jointly led by Beijing Zhongguancun Science City Innovation Development Co.
, Ltd.
and Beijing Innovation Industry Investment Co.

, Ltd.
It is reported that the financing funds will be used to support the NDA application of the company's first CAR-T cell therapy product IM19 with independent intellectual property rights, accelerate the commercialization layout process, and promote the approval of the drug as soon as possible
.
According to the data, the company is an enterprise committed to applying innovative gene cell drug technology to the treatment of
malignant tumors.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.